REST is a novel prognostic factor and therapeutic target for medulloblastoma

Pete Taylor, Jason Fangusaro, Veena Rajaram, Stewart Goldman, Irene B. Helenowski, Tobey MacDonald, Martin Hasselblatt, Lars Riedemann, Alvaro Laureano, Laurence Cooper, Vidya Gopalakrishnan

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Medulloblastoma is a malignant pediatric brain tumor. Current treatment following patient stratification into standard and high-risk groups using clinical features has improved survival. However, a subset of patients with standard risk features have unanticipated aggressive disease, underscoring the need for a better understanding of tumor biology and the development of novel treatments. Poor differentiation, a hallmark of medulloblastomas is associated with elevated expression levels of the repressor of neuronal differentiation called repressor element 1-silencing transcription factor (REST).Here,we assessedwhether elevated REST expression levels had prognostic significance and whether its pharmacologic manipulation would promote neurogenesis and block tumor cell growth.REST levels in patient tumors weremeasured by immunohistochemistry and stratified into negative, low/ moderate- (+/++/+++), and high-REST (+++++) groups. Kaplan-Meier curves revealed that patients with high-REST tumors hadworse overall and event-free survival comparedwith patients withREST-negative orRESTlow tumors. Because histone deacetylases (HDAC) are required for REST-dependent repression of neurogenesis, weevaluateda panel ofHDACinhibitors(HDACI) for their effects ongrowth anddifferentiationof established and primary REST-positive cell lines. MS-275, trichostatin-A (TSA), valproic acid (VPA), and suberoylanilide hydroxamic acid (SAHA) upregulated expression of the REST-target neuronal differentiation gene, Syn1, suggesting a potential effect of these HDACIs on REST function. Interestingly, VPA and TSA substantially increased histone acetylation at the REST promoter and activated its transcription, whereas SAHA unexpectedly promoted its proteasomal degradation. A REST-dependent decrease in cell growth was also observed following SAHA treatment. Thus, our studies suggest that HDACIsmay have therapeutic potential for patients with REST-positive tumors. This warrants further investigation.

Original languageEnglish (US)
Pages (from-to)1713-1723
Number of pages11
JournalMolecular Cancer Therapeutics
Volume11
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Transcriptional Silencer Elements
Medulloblastoma
Transcription Factors
trichostatin A
Therapeutics
Neoplasms
Neurogenesis
Valproic Acid
Histone Deacetylases
Acetylation
Growth
Brain Neoplasms
Histones
Disease-Free Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Taylor, P., Fangusaro, J., Rajaram, V., Goldman, S., Helenowski, I. B., MacDonald, T., ... Gopalakrishnan, V. (2012). REST is a novel prognostic factor and therapeutic target for medulloblastoma. Molecular Cancer Therapeutics, 11(8), 1713-1723. https://doi.org/10.1158/1535-7163.MCT-11-0990

REST is a novel prognostic factor and therapeutic target for medulloblastoma. / Taylor, Pete; Fangusaro, Jason; Rajaram, Veena; Goldman, Stewart; Helenowski, Irene B.; MacDonald, Tobey; Hasselblatt, Martin; Riedemann, Lars; Laureano, Alvaro; Cooper, Laurence; Gopalakrishnan, Vidya.

In: Molecular Cancer Therapeutics, Vol. 11, No. 8, 08.2012, p. 1713-1723.

Research output: Contribution to journalArticle

Taylor, P, Fangusaro, J, Rajaram, V, Goldman, S, Helenowski, IB, MacDonald, T, Hasselblatt, M, Riedemann, L, Laureano, A, Cooper, L & Gopalakrishnan, V 2012, 'REST is a novel prognostic factor and therapeutic target for medulloblastoma', Molecular Cancer Therapeutics, vol. 11, no. 8, pp. 1713-1723. https://doi.org/10.1158/1535-7163.MCT-11-0990
Taylor, Pete ; Fangusaro, Jason ; Rajaram, Veena ; Goldman, Stewart ; Helenowski, Irene B. ; MacDonald, Tobey ; Hasselblatt, Martin ; Riedemann, Lars ; Laureano, Alvaro ; Cooper, Laurence ; Gopalakrishnan, Vidya. / REST is a novel prognostic factor and therapeutic target for medulloblastoma. In: Molecular Cancer Therapeutics. 2012 ; Vol. 11, No. 8. pp. 1713-1723.
@article{a5d6edfae1ea43ff97319cb449e03694,
title = "REST is a novel prognostic factor and therapeutic target for medulloblastoma",
abstract = "Medulloblastoma is a malignant pediatric brain tumor. Current treatment following patient stratification into standard and high-risk groups using clinical features has improved survival. However, a subset of patients with standard risk features have unanticipated aggressive disease, underscoring the need for a better understanding of tumor biology and the development of novel treatments. Poor differentiation, a hallmark of medulloblastomas is associated with elevated expression levels of the repressor of neuronal differentiation called repressor element 1-silencing transcription factor (REST).Here,we assessedwhether elevated REST expression levels had prognostic significance and whether its pharmacologic manipulation would promote neurogenesis and block tumor cell growth.REST levels in patient tumors weremeasured by immunohistochemistry and stratified into negative, low/ moderate- (+/++/+++), and high-REST (+++++) groups. Kaplan-Meier curves revealed that patients with high-REST tumors hadworse overall and event-free survival comparedwith patients withREST-negative orRESTlow tumors. Because histone deacetylases (HDAC) are required for REST-dependent repression of neurogenesis, weevaluateda panel ofHDACinhibitors(HDACI) for their effects ongrowth anddifferentiationof established and primary REST-positive cell lines. MS-275, trichostatin-A (TSA), valproic acid (VPA), and suberoylanilide hydroxamic acid (SAHA) upregulated expression of the REST-target neuronal differentiation gene, Syn1, suggesting a potential effect of these HDACIs on REST function. Interestingly, VPA and TSA substantially increased histone acetylation at the REST promoter and activated its transcription, whereas SAHA unexpectedly promoted its proteasomal degradation. A REST-dependent decrease in cell growth was also observed following SAHA treatment. Thus, our studies suggest that HDACIsmay have therapeutic potential for patients with REST-positive tumors. This warrants further investigation.",
author = "Pete Taylor and Jason Fangusaro and Veena Rajaram and Stewart Goldman and Helenowski, {Irene B.} and Tobey MacDonald and Martin Hasselblatt and Lars Riedemann and Alvaro Laureano and Laurence Cooper and Vidya Gopalakrishnan",
year = "2012",
month = "8",
doi = "10.1158/1535-7163.MCT-11-0990",
language = "English (US)",
volume = "11",
pages = "1713--1723",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - REST is a novel prognostic factor and therapeutic target for medulloblastoma

AU - Taylor, Pete

AU - Fangusaro, Jason

AU - Rajaram, Veena

AU - Goldman, Stewart

AU - Helenowski, Irene B.

AU - MacDonald, Tobey

AU - Hasselblatt, Martin

AU - Riedemann, Lars

AU - Laureano, Alvaro

AU - Cooper, Laurence

AU - Gopalakrishnan, Vidya

PY - 2012/8

Y1 - 2012/8

N2 - Medulloblastoma is a malignant pediatric brain tumor. Current treatment following patient stratification into standard and high-risk groups using clinical features has improved survival. However, a subset of patients with standard risk features have unanticipated aggressive disease, underscoring the need for a better understanding of tumor biology and the development of novel treatments. Poor differentiation, a hallmark of medulloblastomas is associated with elevated expression levels of the repressor of neuronal differentiation called repressor element 1-silencing transcription factor (REST).Here,we assessedwhether elevated REST expression levels had prognostic significance and whether its pharmacologic manipulation would promote neurogenesis and block tumor cell growth.REST levels in patient tumors weremeasured by immunohistochemistry and stratified into negative, low/ moderate- (+/++/+++), and high-REST (+++++) groups. Kaplan-Meier curves revealed that patients with high-REST tumors hadworse overall and event-free survival comparedwith patients withREST-negative orRESTlow tumors. Because histone deacetylases (HDAC) are required for REST-dependent repression of neurogenesis, weevaluateda panel ofHDACinhibitors(HDACI) for their effects ongrowth anddifferentiationof established and primary REST-positive cell lines. MS-275, trichostatin-A (TSA), valproic acid (VPA), and suberoylanilide hydroxamic acid (SAHA) upregulated expression of the REST-target neuronal differentiation gene, Syn1, suggesting a potential effect of these HDACIs on REST function. Interestingly, VPA and TSA substantially increased histone acetylation at the REST promoter and activated its transcription, whereas SAHA unexpectedly promoted its proteasomal degradation. A REST-dependent decrease in cell growth was also observed following SAHA treatment. Thus, our studies suggest that HDACIsmay have therapeutic potential for patients with REST-positive tumors. This warrants further investigation.

AB - Medulloblastoma is a malignant pediatric brain tumor. Current treatment following patient stratification into standard and high-risk groups using clinical features has improved survival. However, a subset of patients with standard risk features have unanticipated aggressive disease, underscoring the need for a better understanding of tumor biology and the development of novel treatments. Poor differentiation, a hallmark of medulloblastomas is associated with elevated expression levels of the repressor of neuronal differentiation called repressor element 1-silencing transcription factor (REST).Here,we assessedwhether elevated REST expression levels had prognostic significance and whether its pharmacologic manipulation would promote neurogenesis and block tumor cell growth.REST levels in patient tumors weremeasured by immunohistochemistry and stratified into negative, low/ moderate- (+/++/+++), and high-REST (+++++) groups. Kaplan-Meier curves revealed that patients with high-REST tumors hadworse overall and event-free survival comparedwith patients withREST-negative orRESTlow tumors. Because histone deacetylases (HDAC) are required for REST-dependent repression of neurogenesis, weevaluateda panel ofHDACinhibitors(HDACI) for their effects ongrowth anddifferentiationof established and primary REST-positive cell lines. MS-275, trichostatin-A (TSA), valproic acid (VPA), and suberoylanilide hydroxamic acid (SAHA) upregulated expression of the REST-target neuronal differentiation gene, Syn1, suggesting a potential effect of these HDACIs on REST function. Interestingly, VPA and TSA substantially increased histone acetylation at the REST promoter and activated its transcription, whereas SAHA unexpectedly promoted its proteasomal degradation. A REST-dependent decrease in cell growth was also observed following SAHA treatment. Thus, our studies suggest that HDACIsmay have therapeutic potential for patients with REST-positive tumors. This warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84864880240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864880240&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-11-0990

DO - 10.1158/1535-7163.MCT-11-0990

M3 - Article

C2 - 22848092

AN - SCOPUS:84864880240

VL - 11

SP - 1713

EP - 1723

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 8

ER -